Making Elimination of Perinatal Hepatitis B Infection a Reality: the Chinese Contribution
Jie Tang,Kuanhui Xiang,Yi-Hua Zhou
DOI: https://doi.org/10.1097/fm9.0000000000000213
2024-01-01
Maternal-Fetal Medicine
Abstract:Chronic hepatitis B virus (HBV) infection, referred to the presence of hepatitis B surface antigen (HBsAg) over 6 months, is a serious health issue because of its severe sequelae such as cirrhosis and hepatocellular carcinoma. Prevention of mother-to-child transmission (MTCT) of HBV is most important to control hepatitis B because a vast majority of HBV acquisition in infancy will become chronic carriers. Since the availability of hepatitis B immunoglobulin (HBIG) in the 1970s and the hepatitis B vaccine in the 1980s, China's central and local health authorities have made tremendous efforts to prevent MTCT of HBV.1 Vaccination against hepatitis B in all newborns was recommended in 1992. After concerted efforts for a decade, free universal hepatitis B vaccination in all infants in China started in 2002. This significantly increased the hepatitis B vaccination coverage in newborns. The coverage of timely birth dose (within 24 hours after birth) increased from 29.1% in 1997 to 75.8% in 2003, and the coverage of a full series of three vaccine doses at a 0-, 1-, and 6-month schedule increased from 70.7% to 89.8%.2 Since 2012, the coverage of timely birth dose and full series has maintained more than 95%.3 Newborns of HBsAg-positive mothers are definitely exposed to HBV during the birth process. Passive immunization of infants with HBIG can immediately provide antibodies to HBsAg to neutralize the exposed viruses. Thus, postexposure immunoprophylaxis, that is, administration of both HBIG and hepatitis B vaccine, is required. HBIG has been used in China since the late 1970s. However, because of the supply shortages, costs charged to parents, low prenatal hepatitis B screening, and insufficient knowledge of preventing MTCT of HBV among health care workers and parents, the administration of HBIG in newborns of HBsAg-positive mothers was suboptimal before 2011, ranging from 37.6% to 69.0% between 2002 and 2011, particularly at economically less prosperous and rural areas.4,5 To overcome the issue of suboptimal use of HBIG in infants, the Chinese central government has implemented a nationwide program to immunize all infants of HBsAg-positive mothers with free HBIG since July 1, 2011. The release of the first Chinese clinical guideline against MTCT of HBV in 2013,6 and the national program to control MTCT of HBV, in addition to HIV and syphilis, launched in 2015,7 enhanced the adherence to recommended passive-active immunoprophylaxis in newborns. An investigation in Jiangsu province showed that the timely (within 24 hours after birth) administration of HBIG was remarkably increased from 76.5% before the program to 98.0% during July 2011 to June 2016.8 Timely administration of HBIG in four provinces, Guangdong, Zhejiang, Shaanxi, and Hebei, representing south, east, west, and north of mainland China, respectively, reached to 99.0% in 2016 and 2017.9 The updated clinical guidelines against MTCT of HBV and national protocol for prevention of MTCT of HIV, syphilis, and HBV recommend use of HBIG in all infants of HBsAg-positive mothers within 12 hours (the sooner, the better) after birth,10,11 instead of 24 hours, as earlier use of immunoprophylaxis has better protective efficacy.12 Although passive-active immunoprophylaxis is highly effective, MTCT of HBV may still occur, that is, immunoprophylaxis failure, which is observed almost all in infants of carrier mothers with HBV DNA >2 × 106 log10 (6.3log10) IU/mL or with positive hepatitis B e antigen (HBeAg).8,12–14 Studies showed that HBeAg-positive carrier mothers have median HBV DNA levels as high as 7 to 8 log10 IU/mL.15,16 Thus, inhibition of HBV replication by antivirals in pregnant women with high viral loads should further reduce MTCT of HBV. Numerous studies demonstrated that perinatal antiviral prophylaxis (PAP), together with neonatal administration of HBIG and hepatitis B vaccine, can almost completely block MTCT of HBV, most of which were conducted by Chinese physicians.17 Since 2020, the use of tenofovir, telbivudine, or lamivudine, with tenofovir as the first choice, initiation from gestation 28 to 32 weeks and discontinuation on delivery day, has been routinely recommended in pregnant women with HBV DNA >2 × 105 (5.3 log10) IU/mL and/or positive HBeAg.10,11 Currently, the coverage rate of PAP is steadily increasing. In the 1980s and early 1990s, the overall prevalence of HBsAg was approximately 10% in general populations in China, corresponding to more than 100 million HBV carriers.1 The prevalence in pregnant women then was the same as that in the general population. With the widespread use of hepatitis B vaccines and other preventive measures, such as safe injection, the prevalence of HBsAg is progressively declining. A province-based survey showed that HBsAg prevalence in pregnant women was reduced to 6.7% in 2002 to 2004.18 The nationwide vigilance of HBsAg in pregnant women covering all counties of mainland China revealed a prevalence of 5.44% in 2020.19 As the HBsAg prevalence among teenagers and young adults aged 15 to 29 years in 2014 was reduced to 4.4%,20 it is anticipated that the prevalence in pregnant women will continue to decline in the coming years, which may result in fewer MTCTs of HBV. The most inspiring achievement after the neonatal immunoprophylaxis and PAP against MTCT of HBV is the dramatic decrease of HBsAg prevalence in children. Historically, HBsAg prevalence peaked at 9.1% in children aged 9 years in cities and at 12.6% in children aged 5 years in rural areas in China.1 After the implementation of immunoprophylaxis, a nationwide survey in 2006 revealed that the HBsAg prevalence among children aged 10 to 14, 5 to 9, and 1 to 4 years was 3.2%, 1.4%, and 1.0%, respectively.21 Another nationwide survey in 2014 found that the prevalence was 0.3% and 0.9% in children at the age of 1 to 4 and 5 to 14 years, respectively.20 And an independent survey in Jiangsu Province in 2014 showed that the prevalence in children aged 0.6 to 3, >3 to 6, >6 to 9, and >9 to 12 years was 0.16%, 0.36%, 0.13, and 1.0%, respectively.22 Moreover, the same 1% prevalence among children aged 1 to 4 years in 200621 and in children aged >9 to 12 years in 201422 suggests that novel chronic HBV infection barely occurred in vaccinated children because 1- to 4-year-old children in 2006 were at the age of 9 to 12 years in 2014. More recently, the interim results of an ongoing serosurvey showed that, of 2576 children aged 7 months to 12 years from February to June 2023, only two children (0.08%) were HBsAg positive, below the goal of 0.1% HBsAg prevalence in children younger than 5 years put forth by the World Health Organization.23 Because PAP against MTCT of HBV in China was not routinely recommended until 2020, currently the overall nationwide PAP rate is suboptimal, even lower than 50% in some rural areas, far from the target rate of ≥90%. However, as China health authorities continue to make every effort to intensify education in health care workers as well as in pregnant women to enhance PAP, we are confident that the elimination of perinatal hepatitis B infection in China will become a reality by 2030.